KLRK1 and neoplasm: Several groups have demonstrated the use of NKG2D-based CAR therapy with unique intracellular signaling domains, such as a second-generation CD3ζ/CD28 (186) or NK-inspired DAP12 (187), to target various tumor and immunosuppressive cells.